Oxford Drug Design Board of Directors announces the appointment of Dr. Alan D. Roth Chief Executive Officer, effective immediately. Alan takes over the position from Dr. Paul W. Finn, who will remain with the company as Chief Scientific Officer. Alan’s career in health sciences comprises executive operations, academic research, investment management/capital markets and strategic consultancy. […]
Oxford Drug Design recently attended both the virtual 3rd RSC-BMCS / RSC-CICAG Artificial Intelligence in Chemistry and UK-QSAR Autumn 2020 meetings. Dr Jerome Wicker presented a poster on AIScape, a machine learning platform for activity and ADME predictions.
Prof. Graham Richards recently spoke to Dr. Michelle Dipp, Co-Founder and Managing Partner of Biospring, on the topic of computer-aided molecular design.
Oxford Drug Design is proud to have been shortlisted for this year’s CogX award for ‘Best AI product in health’. CogX is an annual festival of AI and emerging tech that brings together leaders, entrepreneurs, and policy makers from all sectors to address the problems of the future. CognitionX aims to educate and promote AI […]
Unfortunately due to COVID-19 the events listed have been cancelled. We look forward to meeting you at future events. Oxford Drug Design will be presenting at four events over the next two months: Gordon Research Conference “Disruptive Antibiotics and non-Antibiotic Therapies to Combat Drug-Resistant Bacterial Infections”, 1-6 March, Lucca, Italy. This is one of the […]
Oxford University biotech spin-out receives over £2 million to take its drug discovery programme to the next level. Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised a combined £2.2M in funding from the Angel CoFund (ACF), o2h Ventures and other new investors, and grant funding […]
Oxford Drug Design recently attended an event at the Said Buisness School, in Oxford showcasing the latest developments of Collaborative Drug Discovery’s compound informatics system and ELN. Dr Michael Charlton spoke about our antibacterial projects and how Oxford Drug Design are integrating the collaborative features of CDD into our workflow.
Oxford Drug Design announced today success in securing funds, totalling over £8m, from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the UK Department of Health and Social Care Small Business Research Initiative (SBRI) and equity investment led by o2h Ventures. These funds will be used to advance our dual-target aminoacy-tRNA synthetase inhibitor (DaaRSi) project, which is […]
Dr Michael Charlton recently presented our work in designing novel aminoacyl tRNA synthetase inhibitors at the Chemical Computing Group’s European User Group meeting in Oxford. Michael showed how we use CCG’s MOE modelling software in combination with our own ligand-based virtual screening methods to design novel inhibitors of leucyl tRNA synthetase.
Marco Albanese recently presented a poster on using fragment-based approaches to discover compounds targeting the ATP-binding domain of bacterial histidine kinases at the 7th RSC-BMCS Fragment-based Drug Discovery meeting in Cambridge. Bacterial histidine kinases (HKs) are part of two-component systems (TCSs), the most widespread means by which bacteria sense and adapt to external and internal stimuli. […]